Abstract
Sodium‑glucose co‑transport protein inhibitor Sotagliflozin (SOTA) has demonstrated cardiovascular benefits in diabetic patients, while doxorubicin (DOX) is widely used to generate cardiomyopathy experimental models. The present study investigated the cardioprotective mechanisms of SOTA on DOX‑induced heart failure in vitro and in vivo. First, C57BL/6 mice were injected with multiple doses of DOX (total 15 mg/kg), and the in vivo impact of SOTA on cardiac function and cardiomyopathy‑related biochemical signaling was assessed. Next, H9C2 cells were treated with DOX in the presence of SOTA to examine the changes in cell viability, mitochondrial function, inflammation, oxidative stress and cell death‑related signal pathways. SOTA treatment in vivo alleviated cardiac dysfunction and fibrosis while reducing cardiomyocyte apoptosis, inflammation, oxidative stress and mitochondrial dysfunction. In vitro, H9c2 cells exposed to DOX in the presence of SOTA exhibited enhanced cell viability and mitigated apoptosis, inflammation, oxidative stress and mitochondrial damage. Furthermore, cleaved caspase‑3 and inflammatory cytokine (IL‑6, IL‑1β and TNF‑α) levels were decreased. Reactive oxygen species and mitochondrial Ca2+ loading were reduced. Mitochondrial dysfunction was also improved, as indicated by increased JC‑1 aggregates and Bcl‑2/Bax ratios. Notably, SOTA activated 5' AMP‑activated protein kinase (AMPK) and inhibited mTOR signaling while protecting from DOX‑induced cardiomyopathy, suggesting SOTA as a promising therapeutic for heart failure treatment.

This publication has 73 references indexed in Scilit: